Acthar

( DrugBank: - / KEGG DRUG: - )

---

9 diseases

2. 筋萎縮性側索硬化症

---

臨床試験数 : 786 / 薬物数 : 550 - (DrugBank : 182) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 232 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

---

臨床試験数 : 223 / 薬物数 : 119 - (DrugBank : 28) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 22 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

46. 悪性関節リウマチ

---

臨床試験数 : 4,543 / 薬物数 : 2,251 - (DrugBank : 390) / 標的遺伝子数 : 198 - 標的パスウェイ数 : 232 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

49. 全身性エリテマトーデス

---

臨床試験数 : 1,227 / 薬物数 : 752 - (DrugBank : 175) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 207 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

50. 皮膚筋炎／多発性筋炎

---

臨床試験数 : 231 / 薬物数 : 216 - (DrugBank : 55) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 141 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

66. IgA腎症

---

臨床試験数 : 349 / 薬物数 : 251 - (DrugBank : 75) / 標的遺伝子数 : 43 - 標的パスウェイ数 : 152 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

84. サルコイドーシス

---

臨床試験数 : 175 / 薬物数 : 189 - (DrugBank : 80) / 標的遺伝子数 : 74 - 標的パスウェイ数 : 177 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

222. 一次性ネフローゼ症候群

---

臨床試験数 : 382 / 薬物数 : 278 - (DrugBank : 98) / 標的遺伝子数 : 73 - 標的パスウェイ数 : 197 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries